Welcome!
3Q2021
Results
Tianjin Zhongxin Pharma's 3Q2021 earnings rise 30% to $41.8mil on higher sales
In 9M2021, net attributable profit stood at RMB661.5 million, a 39% increase y-o-y.
October 29, 2021
Investing strategies
DBS CIO likes European equities for strong recovery; stays positive on S-REITs
DBS is optimistic that the time is near for investors to see the start of recovery.
July 02, 2021